Vimentin positive/CD45 negative cells were detected in four of five cancer patient samples used for this analysis and 0%, 15.7%, 27.8%, 71.4% and 92.9% of CK positive CTCs expressed Vimentin in these five patients, including three metastatic prostate cancer patients in treatment and two newly diagnosed untreated prostate cancer patients (Tables 1 and 6). Here, VIM is linked to metastatic prostate carcinoma.